Clinical trial
IBEX: Phase 2 Trial of Iberdomide + SQ Daratumumab as Post-Autologous Stem Cell Transplant Maintenance Therapy in Multiple Myeloma
NCT06107738 is registered in ClinicalTrials.gov with Barbara Ann Karmanos Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- IBEX: Phase 2 Trial of Iberdomide + SQ Daratumumab as Post-Autologous Stem Cell Transplant Maintenance Therapy in Multiple Myeloma
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- December 21, 2023
- Completion date
- December 31, 2028
- Enrollment
- 60 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.